JP6730252B2 - 多発性嚢胞腎のバイオマーカーおよびその使用 - Google Patents

多発性嚢胞腎のバイオマーカーおよびその使用 Download PDF

Info

Publication number
JP6730252B2
JP6730252B2 JP2017506291A JP2017506291A JP6730252B2 JP 6730252 B2 JP6730252 B2 JP 6730252B2 JP 2017506291 A JP2017506291 A JP 2017506291A JP 2017506291 A JP2017506291 A JP 2017506291A JP 6730252 B2 JP6730252 B2 JP 6730252B2
Authority
JP
Japan
Prior art keywords
pkd
patient
cyclin
level
time point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017506291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525955A5 (enExample
JP2017525955A (ja
Inventor
オクサナ・ベスクロヴナヤ
ニコライ・バカノフ
サラ・モレノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2017525955A publication Critical patent/JP2017525955A/ja
Publication of JP2017525955A5 publication Critical patent/JP2017525955A5/ja
Application granted granted Critical
Publication of JP6730252B2 publication Critical patent/JP6730252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2017506291A 2014-08-04 2015-08-03 多発性嚢胞腎のバイオマーカーおよびその使用 Active JP6730252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
US62/033,031 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020113693A Division JP7005695B2 (ja) 2014-08-04 2020-07-01 多発性嚢胞腎のバイオマーカーおよびその使用

Publications (3)

Publication Number Publication Date
JP2017525955A JP2017525955A (ja) 2017-09-07
JP2017525955A5 JP2017525955A5 (enExample) 2018-09-13
JP6730252B2 true JP6730252B2 (ja) 2020-07-29

Family

ID=54035292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017506291A Active JP6730252B2 (ja) 2014-08-04 2015-08-03 多発性嚢胞腎のバイオマーカーおよびその使用
JP2020113693A Active JP7005695B2 (ja) 2014-08-04 2020-07-01 多発性嚢胞腎のバイオマーカーおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020113693A Active JP7005695B2 (ja) 2014-08-04 2020-07-01 多発性嚢胞腎のバイオマーカーおよびその使用

Country Status (12)

Country Link
US (1) US10871495B2 (enExample)
EP (1) EP3177932B1 (enExample)
JP (2) JP6730252B2 (enExample)
KR (1) KR20170033436A (enExample)
CN (1) CN106716136B (enExample)
AU (1) AU2015301278A1 (enExample)
BR (1) BR112017002003A2 (enExample)
CO (1) CO2017001596A2 (enExample)
MX (1) MX2017001648A (enExample)
RU (1) RU2017106891A (enExample)
SG (1) SG11201700290SA (enExample)
WO (1) WO2016022500A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500418A (ja) * 1999-05-24 2003-01-07 エイブイアイ バイオファーマ， インコーポレイテッド 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
US20120077263A1 (en) 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) * 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
US20140079769A1 (en) * 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
ES2982997T3 (es) 2012-07-03 2024-10-21 Fond Centro San Raffaele 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد

Also Published As

Publication number Publication date
EP3177932A2 (en) 2017-06-14
JP2020170013A (ja) 2020-10-15
RU2017106891A3 (enExample) 2019-03-14
RU2017106891A (ru) 2018-09-06
EP3177932B1 (en) 2021-07-14
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
BR112017002003A2 (pt) 2017-12-12
CN106716136B (zh) 2020-06-23
KR20170033436A (ko) 2017-03-24
US20170227551A1 (en) 2017-08-10
MX2017001648A (es) 2017-04-27
US10871495B2 (en) 2020-12-22
CO2017001596A2 (es) 2017-05-19
WO2016022500A3 (en) 2016-04-07
SG11201700290SA (en) 2017-02-27
WO2016022500A2 (en) 2016-02-11
JP2017525955A (ja) 2017-09-07
AU2015301278A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US12150938B2 (en) Biomarker of polycystic kidney disease and uses thereof
JP5893742B2 (ja) 早期における急性腎損傷をモニタリング、診断、および／または予後診断するための方法
JP7005695B2 (ja) 多発性嚢胞腎のバイオマーカーおよびその使用
Schilder et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied
JP2019502902A5 (enExample)
Park et al. Regulation of phosphorylation of glycogen synthase kinase 3α and the correlation with sperm motility in human
Kocyigit et al. Association of OSR‐1 With Vascular Dysfunction and Hypertension in Polycystic Kidney Disease
Chen et al. GM130-silencing may aggravate blood-brain barrier damage and affect microglia polarization by down-regulating PD-L1 expression after experimental intracerebral hemorrhage
Majid et al. Diagnostic potential of serum biomarkers including HMGB1 and Klotho in cognitive impairment among type 2 diabetes mellitus patients: a case–control study
Ikeda Relation of CSF Folate Metabolism in Various Neuropsychiatric Conditions and Multiple Sclerosis
Raslan et al. Effect of Modified Ultrafiltration on Acute Kidney Injury Biomarkers and Clinical Outcome in Adult Patients Undergoing Valvular Heart Surgery
UA126973U (uk) Спосіб діагностики розвитку атеросклерозу
Islam et al. Spontaneous Bacterial Peritonitis and Proton Pump Inhibitors: Correlation of Disease Process?
Gerber et al. Association of Serum Biomarkers With Fatigue in Patients With Chronic Liver Disease
Park et al. The Influence of Hemodialysis to Prognosis of Patients With Severe Alcoholic Lactic Acidosis
UA127840U (uk) Спосіб діагностики розвитку атеросклерозу
UA127859U (uk) Спосіб діагностики розвитку атеросклерозу
UA128172U (uk) Спосіб діагностики розвитку атеросклерозу
UA127752U (uk) Спосіб діагностики розвитку атеросклерозу
UA125906U (uk) Спосіб діагностики розвитку атеросклерозу
UA121225U (uk) Спосіб діагностики розвитку атеросклерозу
UA122097U (uk) Спосіб діагностики розвитку атеросклерозу
UA122012U (uk) Спосіб діагностики розвитку атеросклерозу
UA127793U (uk) Спосіб діагностики розвитку атеросклерозу
UA121234U (uk) Спосіб діагностики розвитку атеросклерозу

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200702

R150 Certificate of patent or registration of utility model

Ref document number: 6730252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250